NASDAQ:ABCL AbCellera Biologics (ABCL) Stock Price, News & Analysis → What is Medicare Supplement Insurance? (From Tranzact) (Ad) Free ABCL Stock Alerts $3.76 +0.13 (+3.58%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$3.64▼$3.8050-Day Range$3.63▼$5.3452-Week Range$3.62▼$8.05Volume1.37 million shsAverage Volume1.08 million shsMarket Capitalization$1.10 billionP/E RatioN/ADividend YieldN/APrice Target$15.86 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get AbCellera Biologics alerts: Email Address AbCellera Biologics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside321.7% Upside$15.86 Price TargetShort InterestBearish11.25% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.34Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.66) to ($0.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.75 out of 5 starsMedical Sector630th out of 913 stocksPharmaceutical Preparations Industry287th out of 423 stocks 3.5 Analyst's Opinion Consensus RatingAbCellera Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAbCellera Biologics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.25% of the float of AbCellera Biologics has been sold short.Short Interest Ratio / Days to CoverAbCellera Biologics has a short interest ratio ("days to cover") of 17.4, which indicates bearish sentiment.Change versus previous monthShort interest in AbCellera Biologics has recently decreased by 2.12%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAbCellera Biologics does not currently pay a dividend.Dividend GrowthAbCellera Biologics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABCL. Previous Next 0.9 News and Social Media Coverage News SentimentAbCellera Biologics has a news sentiment score of -0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for AbCellera Biologics this week, compared to 2 articles on an average week.Search InterestOnly 17 people have searched for ABCL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added AbCellera Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AbCellera Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders32.45% of the stock of AbCellera Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.42% of the stock of AbCellera Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AbCellera Biologics are expected to decrease in the coming year, from ($0.66) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AbCellera Biologics is -7.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AbCellera Biologics is -7.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbCellera Biologics has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About AbCellera Biologics Stock (NASDAQ:ABCL)AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, as well as strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Read More ABCL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABCL Stock News HeadlinesApril 27, 2024 | americanbankingnews.comAbCellera Biologics (NASDAQ:ABCL) Hits New 52-Week Low at $3.76April 20, 2024 | americanbankingnews.comAbCellera Biologics (NASDAQ:ABCL) Hits New 1-Year Low at $3.84April 27, 2024 | Tranzact (Ad)What is Medicare Supplement Insurance?Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. April 18, 2024 | finance.yahoo.comAbCellera Biologics Inc. (ABCL)April 8, 2024 | businesswire.comAbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024April 3, 2024 | businesswire.comAbCellera to Report First Quarter 2024 Financial Results on May 7, 2024March 27, 2024 | investorplace.comThe 7 Best Penny Stocks to Buy in Q2 2024March 27, 2024 | finance.yahoo.comBillionaire Investor Stan Druckenmiller and Insiders Are Piling Into These 11 StocksApril 27, 2024 | Tranzact (Ad)What is Medicare Supplement Insurance?Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. March 19, 2024 | businesswire.comAbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024March 11, 2024 | msn.comAbCellera gains on antibody collaboration with BiogenMarch 5, 2024 | businesswire.comAbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024February 29, 2024 | finance.yahoo.comAfter losing 38% in the past year, AbCellera Biologics Inc. (NASDAQ:ABCL) institutional owners must be relieved by the recent gainFebruary 28, 2024 | seekingalpha.comAbCellera: Victim Of Its Own SuccessFebruary 26, 2024 | investorplace.com3 Highly Rated Biotech Stocks to Buy for 300% GainsFebruary 23, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)February 23, 2024 | businesswire.comAbCellera Announces Resignation of Board MemberFebruary 23, 2024 | finance.yahoo.comABCL Mar 2024 4.000 callFebruary 23, 2024 | finance.yahoo.comABCL Mar 2024 5.000 callFebruary 23, 2024 | msn.comBenchmark Upgrades AbCellera Biologics (ABCL)February 22, 2024 | benzinga.comAbCellera Biologics Stock (NASDAQ:ABCL) Earnings Dates and Earning CallsFebruary 22, 2024 | businesswire.comAbCellera to Present at Upcoming Investor Conferences in MarchFebruary 22, 2024 | msn.comObesity drugs to expand U.S. GDP by 1% in the coming years: Goldman SachsFebruary 22, 2024 | benzinga.comAbCellera Biologics Stock (NASDAQ:ABCL) Insider TradesFebruary 22, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)February 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), GeneDx Holdings (WGS) and Halozyme (HALO)February 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Halozyme (HALO) and AbCellera Biologics (ABCL)See More Headlines Receive ABCL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today4/27/2024Next Earnings (Confirmed)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ABCL CUSIPN/A CIK1703057 Webwww.abcellera.com Phone604-559-9005FaxN/AEmployees586Year FoundedN/APrice Target and Rating Average Stock Price Target$15.86 High Stock Price Target$24.00 Low Stock Price Target$6.00 Potential Upside/Downside+321.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-146,400,000.00 Net Margins-384.99% Pretax Margin-457.67% Return on Equity-12.36% Return on Assets-9.70% Debt Debt-to-Equity RatioN/A Current Ratio7.33 Quick Ratio7.33 Sales & Book Value Annual Sales$38.03 million Price / Sales28.95 Cash FlowN/A Price / Cash FlowN/A Book Value$3.97 per share Price / Book0.95Miscellaneous Outstanding Shares292,780,000Free Float197,774,000Market Cap$1.10 billion OptionableOptionable Beta0.36 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Carl L.G. Hansen Ph.D. (Age 49)CEO, President & Chairperson Comp: $711.47kMr. Andrew Booth M.B.A. (Age 50)Chief Financial Officer Comp: $642.42kDr. Veronique Lecault Ph.D. (Age 39)COO & Director Comp: $645.07kMr. Tryn T. Stimart Esq. (Age 54)J.D., M.Sc., Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer Comp: $644.4kMr. Neil Aubuchon B.A. (Age 53)M.B.A., Chief Commercial Officer Comp: $684.81kMarcie Thiessen CPACGA, Senior Director of Finance & AccountingDr. Ester Falconer Ph.D. (Age 49)Chief Technology Officer Kathleen Reid B.A.Head of Corporate CommunicationsGraham Craig M.Sc.Director of Corporate DevelopmentMr. Murray McCutcheon Ph.D.Senior Vice President of PartneringMore ExecutivesKey CompetitorsGemini TherapeuticsNASDAQ:GMTXCollegium PharmaceuticalNASDAQ:COLLMirum PharmaceuticalsNASDAQ:MIRMDeciphera PharmaceuticalsNASDAQ:DCPHPieris PharmaceuticalsNASDAQ:PIRSView All CompetitorsInsiders & InstitutionsPFG Investments LLCBought 16,600 shares on 4/22/2024Ownership: 0.006%TrueMark Investments LLCBought 13,104 shares on 4/15/2024Ownership: 0.038%Pacifica Partners Inc.Bought 3,799 shares on 4/12/2024Ownership: 0.003%B. Riley Wealth Advisors Inc.Bought 9,000 shares on 3/15/2024Ownership: 0.007%Tower Research Capital LLC TRC Sold 2,186 shares on 2/13/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions ABCL Stock Analysis - Frequently Asked Questions Should I buy or sell AbCellera Biologics stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ABCL shares. View ABCL analyst ratings or view top-rated stocks. What is AbCellera Biologics' stock price target for 2024? 7 brokerages have issued 12-month price objectives for AbCellera Biologics' shares. Their ABCL share price targets range from $6.00 to $24.00. On average, they predict the company's share price to reach $15.86 in the next twelve months. This suggests a possible upside of 321.7% from the stock's current price. View analysts price targets for ABCL or view top-rated stocks among Wall Street analysts. How have ABCL shares performed in 2024? AbCellera Biologics' stock was trading at $5.71 at the beginning of 2024. Since then, ABCL stock has decreased by 34.2% and is now trading at $3.76. View the best growth stocks for 2024 here. When is AbCellera Biologics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our ABCL earnings forecast. How can I listen to AbCellera Biologics' earnings call? AbCellera Biologics will be holding an earnings conference call on Tuesday, May 7th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link. How were AbCellera Biologics' earnings last quarter? AbCellera Biologics Inc. (NASDAQ:ABCL) posted its quarterly earnings data on Tuesday, February, 20th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.03. The business had revenue of $9.18 million for the quarter, compared to analyst estimates of $9.58 million. AbCellera Biologics had a negative net margin of 384.99% and a negative trailing twelve-month return on equity of 12.36%. What ETFs hold AbCellera Biologics' stock? ETFs with the largest weight of AbCellera Biologics (NASDAQ:ABCL) stock in their portfolio include TrueShares Technology, AI & Deep Learning ETF (LRNZ).iShares Genomics Immunology and Healthcare ETF (IDNA). When did AbCellera Biologics IPO? AbCellera Biologics (ABCL) raised $356 million in an initial public offering on Friday, December 11th 2020. The company issued 23,000,000 shares at $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO. Who are AbCellera Biologics' major shareholders? AbCellera Biologics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include TrueMark Investments LLC (0.04%), PFG Investments LLC (0.01%) and Pacifica Partners Inc. (0.00%). Insiders that own company stock include Andrew Booth, Andrew Lo, Carl L G Hansen, Holdings Ltd Thermopylae, John Hamer, John S Montalbano, Michael R Hayden and Veronique Lecault. View institutional ownership trends. How do I buy shares of AbCellera Biologics? Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ABCL) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
